Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) · developed by MacroGenics
Vobramitamab tavatecan is an antibody-drug conjugate in which a humanized antibody binds B7-H3 (CD276), a protein overexpressed on certain tumor cells, and delivers the topoisomerase I inhibitor exatecan via a cleavable linker. It is being studied in advanced solid tumors, including non-small cell lung cancer, small-cell lung cancer, prostate, bladder, and colorectal cancers, among others.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06242470 | Phase 1 | Advanced Solid Tumor | Recruiting | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced CancerAdvanced Solid TumorBladder CancerCastration Resistant Prostatic CancerCervical CancerColorectal CancerEndometrial CancerGastric CancerGastro-esophageal CancerMelanomaMetastatic CancerNon Small Cell Lung CancerSarcomaSmall-cell Lung Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →